SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Canalis E 1996 Clinical review 83: Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81:34413447.
  • 2
    Manolagas SC 2000 Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115137.
  • 3
    Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:43824389.
  • 4
    Carbonare LD, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ 2001 Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97103.
  • 5
    van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C 2000 Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:9931000.
  • 6
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382387.
  • 7
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292299.
  • 8
    Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA 2000 Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277285.
  • 9
    Cooper C, Melton JL III 1996 Magnitude and impact of osteoporosis and fractures. In: MarcusR, FeldmanD, KelseyJ (eds.) Osteoporosis. Academic Press, San Diego, CA, USA, pp. 421425.
  • 10
    Brockstedt H, Kassem M, Eriksen EF, Mosekilde L, Melsen F 1993 Age- and sex-related changes in iliac cortical bone mass and remodeling. Bone 14:681691.
  • 11
    Clarke BL, Ebeling PR, Jones JD, Wahner HW, O'Fallon WM, Riggs BL, Fitzpatrick LA 1996 Changes in quantitative bone histomorphometry in aging healthy men. J Clin Endocrinol Metab 81:22642270.
  • 12
    Ferrari E, Cravello L, Muzzoni B, Casarotti D, Paltro M, Solerte SB, Fioravanti M, Cuzzoni G, Pontiggia B, Magri F 2001 Age-related changes of the hypothalamic-pituitary-adrenal axis: Pathophysiological correlates. Eur J Endocrinol 144:319329.
  • 13
    Stewart PM, Krozowski ZS 1999 11β-Hydroxysteroid dehydrogenase. Vitam Horm 57:249324.
  • 14
    Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M, Stewart PM 2000 Expression and functional consequences of 11β-hydroxysteroid dehydrogenase activity in human bone. Bone 27:375381.
  • 15
    Bland R, Worker CA, Noble BS, Eyre LJ, Bujalska IJ, Sheppard MC, Stewart PM, Hewison M 1999 Characterization of 11β-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. J Endocrinol 161:455464.
  • 16
    Eyre LJ, Rabbitt EH, Bland R, Hughes SV, Cooper MS, Sheppard MC, Stewart PM, Hewison M 2001 Expression of 11β-hydroxysteroid dehydrogenase in rat osteoblastic cells: Pre-receptor regulation of glucocorticoid responses in bone. J Cell Biochem 81:453462.
  • 17
    Cooper MS, Bujalska I, Rabbitt E, Walker EA, Bland R, Sheppard MC, Hewison M, Stewart PM 2001 Modulation of 11β-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: An autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res 16:10371044.
  • 18
    Rabbitt E, Lavery GG, Walker EA, Cooper MS, Stewart PM, Hewison M 2002 Pre-receptor regulation of glucocorticoid action by 11β-hydroxysteroid dehydrogenase: A novel determinant of cell proliferation. FASEB J 16:3644.
  • 19
    Bujalska IJ, Kumar S, Stewart PM 1997 Does central obesity reflect “Cushing's disease of the omentum”? Lancet 349:12101213.
  • 20
    Hammami MM, Siiteri PK 1991 Regulation of 11 β-hydroxysteroid dehydrogenase activity in human skin fibroblasts: Enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 73:326334.
  • 21
    Jamieson PM, Chapman KE, Edwards CR, Seckl JR 1995 11β-hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of rat hepatocytes: Effect of physicochemical and hormonal manipulations. Endocrinology 136:47544761.
  • 22
    Liu YJ, Nakagawa Y, Nasuda K, Saegusa H, Igarashi Y 1996 Effect of growth hormone, insulin and dexamethasone on 11β-hydroxysteroid dehydrogenase activity on a primary culture of rat hepatocytes. Life Sci 59:227234.
  • 23
    Bujalska IJ, Kumar S, Hewison M, Stewart PM 1999 Differentiation of adipose stromal cells: The roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 140:31883196.
  • 24
    van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C 2000 Use of oral corticosteroids in the United Kingdom. QJM 93:105111.
  • 25
    Robey PG, Termine JD 1985 Human bone cells in vitro. Calcif Tissue Int 37:453460.
  • 26
    Bujalska I, Shimojo M, Howie A, Stewart PM 1997 Human 11β-hydroxysteroid dehydrogenase: Studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 62:7782.
  • 27
    Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248254.
  • 28
    Bayly GR, Bartlett WA, Jones AF 1997 A non-isotopic method for estimating 11β-hydroxysteroid dehydrogenase activity in vivo. Ann Clin Biochem 34:521526.
  • 29
    Martinez ME, Del Campo MT, Medina S, Sanchez M, Sanchez-Cabezudo MJ, Esbrit P, Martinez P, Moreno I, Rodrigo A, Garces MV, Munuera L 1999 Influence of skeletal site of origin and donor age on osteoblastic cell growth and differentiation. Calcif Tissue Int 64:280286.
  • 30
    Van Cauter E, Leproult R, Kupfer DJ 1996 Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab 81:24682473.
  • 31
    Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294:21662170.
  • 32
    Napolitano A, Voice MW, Edwards CR, Seckl JR, Chapman KE 1998 11β-hydroxysteroid dehydrogenase 1 in adipocytes: Expression is differentiation-dependent and hormonally regulated. J Steroid Biochem Mol Biol 64:251260.
  • 33
    Jamieson PM, Chapman KE, Seckl JR 1999 Tissue- and temporal-specific regulation of 11β-hydroxysteroid dehydrogenase type 1 by glucocorticoids in vivo. J Steroid Biochem Mol Biol 68:245250.
  • 34
    Jenkins JS, Sampson PA 1967 Conversion of cortisone to cortisol and prednisone to prednisolone. BMJ 2:205207.
  • 35
    Hult M, Jornvall H, Oppermann UC 1998 Selective inhibition of human type 1 11β-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett 441:2528.
  • 36
    Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CR 1992 Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 37:483492.
  • 37
    Gambertoglio JG, Amend WJ Jr, Benet LZ 1980 Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: A review. J Pharmacokinet Biopharm 8:152.
  • 38
    Ballard PL 1979 Delivery and transport of glucocorticoids to target cells. In: BaxterJD, RousseauGG (eds.) Glucocorticoid Hormone Action. Springer-Verlag, Berlin, pp. 2548.
  • 39
    Andrews RC, Walker BR 1999 Glucocorticoids and insulin resistance: Old hormones, new targets. Clin Sci (Colch) 96:513523.
  • 40
    Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV 1984 Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans. Calcif Tissue Int 36:245252.
  • 41
    Lo CV, Bonucci E, Imbimbo B, Ballanti P, Tartarotti D, Galvanini G, Fuccella L, Adami S 1984 Bone loss after glucocorticoid therapy. Calcif Tissue Int 36:435438.
  • 42
    Lippuner K, Casez JP, Horber FF, Jaeger P 1998 Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: A randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab 83:37953802.
  • 43
    Anonymous 1999 Deflazacort—an alternative to prednisolone? Drug Ther Bull 37:5758.